Valuation : Lundbeck

Market Cap 42.67B 6.62B 5.71B 5.37B 4.89B 9.2B 628B 9.25B 63.49B 24.71B 320B 24.85B 24.31B 1,059B P/E 2026 *
9.5x
P/E 2027 * 9.33x
Enterprise Value 46.67B 7.24B 6.24B 5.87B 5.35B 10.06B 687B 10.12B 69.44B 27.03B 349B 27.18B 26.59B 1,159B EV / Sales 2026 *
1.8x
EV / Sales 2027 * 1.63x
Free-Float
30.74%
Yield 2026 *
3.6%
Yield 2027 * 3.24%
1 day-0.72%
1 week-3.00%
Current month-1.79%
1 month+14.38%
3 months+12.38%
6 months+17.68%
Current year+13.66%
1 week 5.48
Extreme 5.48
5.72
1 month 4.72
Extreme 4.715
5.72
Current year 4.22
Extreme 4.22
5.72
1 year 4.22
Extreme 4.22
5.72
3 years 3.12
Extreme 3.125
5.72
5 years 3.03
Extreme 3.028
10.99
10 years 3.03
Extreme 3.028
10.99
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 67 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%-3.00% - - 6.49B
+2.53%+0.19%+32.06%+119.91% 103B
+2.02%+0.60%+60.88%+173.29% 54.57B
-0.18%-4.40%-12.14%+243.67% 22.16B
+0.86%+0.12%-11.36%-8.13% 8.07B
+0.44%+0.37%-39.76%-28.23% 7.11B
+2.27%+1.12%+7.04%+22.61% 6.49B
-0.97%-5.09%-17.30%-33.48% 6.17B
0.00%-0.30%-3.37%+19.57% 5.12B
+1.35%+13.71%+288.51%+459.14% 4.29B
Average +0.80%+0.85%+33.84%+107.60% 24.13B
Weighted average by Cap. +1.77%+0.41%+32.91%+133.41%

Financials

2026 *2027 *
Net sales 25.92B 4.02B 3.47B 3.26B 2.97B 5.59B 382B 5.62B 38.56B 15.01B 194B 15.09B 14.77B 644B 26.05B 4.04B 3.49B 3.28B 2.99B 5.62B 384B 5.65B 38.76B 15.09B 195B 15.17B 14.84B 647B
Net income 4.59B 711M 614M 577M 526M 989M 67.51B 994M 6.82B 2.66B 34.34B 2.67B 2.61B 114B 4.65B 721M 622M 585M 533M 1B 68.43B 1.01B 6.92B 2.69B 34.81B 2.71B 2.65B 115B
Net Debt 4B 621M 536M 504M 459M 863M 58.93B 868M 5.96B 2.32B 29.97B 2.33B 2.28B 99.39B -178M -27.56M -23.78M -22.37M -20.38M -38.32M -2.62B -38.52M -264M -103M -1.33B -103M -101M -4.41B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
26-09-01 €5.710 +2.15%
26-08-31 €5.590 +1.82%
26-08-28 €5.490 -0.72%
26-08-27 €5.530 -0.18%
26-08-26 €5.540 -2.12%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
43.16DKK
Average target price
48.73DKK
Spread / Average Target
+12.91%

Quarterly revenue - Rate of surprise